BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 36074460)

  • 1. Constitutional BRCA1 Methylation and Risk of Incident Triple-Negative Breast Cancer and High-grade Serous Ovarian Cancer.
    Lønning PE; Nikolaienko O; Pan K; Kurian AW; Eikesdal HP; Pettinger M; Anderson GL; Prentice RL; Chlebowski RT; Knappskog S
    JAMA Oncol; 2022 Nov; 8(11):1579-1587. PubMed ID: 36074460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Constitutional
    Al-Moghrabi N; Al-Showimi M; Alqahtani A; Almalik O; Alhusaini H; Almalki G; Saad A; Alsunayi E
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contribution of constitutional BRCA1 promoter methylation to early-onset and familial breast cancer patients from Pakistan.
    Muhammad N; Azeem A; Bakar MA; Prajzendanc K; Loya A; Jakubowska A; Hamann U; Rashid MU
    Breast Cancer Res Treat; 2023 Nov; 202(2):377-387. PubMed ID: 37528266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. White Blood Cell BRCA1 Promoter Methylation Status and Ovarian Cancer Risk.
    Lønning PE; Berge EO; Bjørnslett M; Minsaas L; Chrisanthar R; Høberg-Vetti H; Dulary C; Busato F; Bjørneklett S; Eriksen C; Kopperud R; Axcrona U; Davidson B; Bjørge L; Evans G; Howell A; Salvesen HB; Janszky I; Hveem K; Romundstad PR; Vatten LJ; Tost J; Dørum A; Knappskog S
    Ann Intern Med; 2018 Mar; 168(5):326-334. PubMed ID: 29335712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers.
    Przybytkowski E; Davis T; Hosny A; Eismann J; Matulonis UA; Wulf GM; Nabavi S
    BMC Cancer; 2020 Mar; 20(1):197. PubMed ID: 32164626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic Inactivation of BRCA1 Through Promoter Hypermethylation and Its Clinical Importance in Triple-Negative Breast Cancer.
    Yamashita N; Tokunaga E; Kitao H; Hitchins M; Inoue Y; Tanaka K; Hisamatsu Y; Taketani K; Akiyoshi S; Okada S; Oda Y; Saeki H; Oki E; Maehara Y
    Clin Breast Cancer; 2015 Dec; 15(6):498-504. PubMed ID: 26195437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Somatic Mutational Profile of High-Grade Serous Ovarian Carcinoma and Triple-Negative Breast Carcinoma in Young and Elderly Patients: Similarities and Divergences.
    Serio PAMP; de Lima Pereira GF; Katayama MLH; Roela RA; Maistro S; Folgueira MAAK
    Cells; 2021 Dec; 10(12):. PubMed ID: 34944094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prenatal BRCA1 epimutations contribute significantly to triple-negative breast cancer development.
    Nikolaienko O; Eikesdal HP; Ognedal E; Gilje B; Lundgren S; Blix ES; Espelid H; Geisler J; Geisler S; Janssen EAM; Yndestad S; Minsaas L; Leirvaag B; Lillestøl R; Knappskog S; Lønning PE
    Genome Med; 2023 Dec; 15(1):104. PubMed ID: 38053165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRCA1 promoter methylation in peripheral blood is associated with the risk of triple-negative breast cancer.
    Prajzendanc K; Domagała P; Hybiak J; Ryś J; Huzarski T; Szwiec M; Tomiczek-Szwiec J; Redelbach W; Sejda A; Gronwald J; Kluz T; Wiśniowski R; Cybulski C; Łukomska A; Białkowska K; Sukiennicki G; Kulczycka K; Narod SA; Wojdacz TK; Lubiński J; Jakubowska A
    Int J Cancer; 2020 Mar; 146(5):1293-1298. PubMed ID: 31469414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Constitutional Mosaic Epimutations - a hidden cause of cancer?
    Lønning PE; Eikesdal HP; Løes IM; Knappskog S
    Cell Stress; 2019 Mar; 3(4):118-135. PubMed ID: 31225507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triple-negative breast cancer and PTEN (phosphatase and tensin homologue) loss are predictors of BRCA1 germline mutations in women with early-onset and familial breast cancer, but not in women with isolated late-onset breast cancer.
    Phuah SY; Looi LM; Hassan N; Rhodes A; Dean S; Taib NA; Yip CH; Teo SH
    Breast Cancer Res; 2012 Nov; 14(6):R142. PubMed ID: 23116406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic evaluation of BRCA1 associated a complex genes with triple-negative breast cancer susceptibility in Chinese women.
    Ling H; Li S; Wu Y; Zheng YZ; Qiao F; Yao L; Cao ZG; Ye FG; Wu J; Hu X; Wang B; Shao ZM
    Oncotarget; 2016 Mar; 7(9):9759-72. PubMed ID: 26848770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methylation of the BRCA1 promoter in peripheral blood DNA is associated with triple-negative and medullary breast cancer.
    Gupta S; Jaworska-Bieniek K; Narod SA; Lubinski J; Wojdacz TK; Jakubowska A
    Breast Cancer Res Treat; 2014 Dec; 148(3):615-22. PubMed ID: 25376744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients.
    Rashid MU; Muhammad N; Bajwa S; Faisal S; Tahseen M; Bermejo JL; Amin A; Loya A; Hamann U
    BMC Cancer; 2016 Aug; 16(1):673. PubMed ID: 27553291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Curcumin induces re‑expression of BRCA1 and suppression of γ synuclein by modulating DNA promoter methylation in breast cancer cell lines.
    Al-Yousef N; Shinwari Z; Al-Shahrani B; Al-Showimi M; Al-Moghrabi N
    Oncol Rep; 2020 Mar; 43(3):827-838. PubMed ID: 32020216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients--a study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD).
    Ruscito I; Dimitrova D; Vasconcelos I; Gellhaus K; Schwachula T; Bellati F; Zeillinger R; Benedetti-Panici P; Vergote I; Mahner S; Cacsire-Tong D; Concin N; Darb-Esfahani S; Lambrechts S; Sehouli J; Olek S; Braicu EI
    Eur J Cancer; 2014 Aug; 50(12):2090-8. PubMed ID: 24889916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promoter hypermethylation of p16, BRCA1 and RASSF1A genes in triple-negative breast cancer patients from Serbia.
    Kozomara Z; Supic G; Krivokuca A; Magic Z; Dzodic R; Milovanovic Z; Brankovic-Magic M
    J BUON; 2018; 23(3):684-691. PubMed ID: 30003738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRCA1 promoter methylation is a marker of better response to anthracycline-based therapy in sporadic TNBC.
    Ignatov T; Poehlmann A; Ignatov A; Schinlauer A; Costa SD; Roessner A; Kalinski T; Bischoff J
    Breast Cancer Res Treat; 2013 Sep; 141(2):205-12. PubMed ID: 24026861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRCA1 Mutation Leads to Deregulated Ubc9 Levels which Triggers Proliferation and Migration of Patient-Derived High Grade Serous Ovarian Cancer and Triple Negative Breast Cancer Cells.
    Xu J; Footman A; Qin Y; Aysola K; Black S; Reddy V; Singh K; Grizzle W; You S; Moellering D; Reddy ES; Fu Y; Rao VN
    Int J Chronic Dis Ther; 2016; 2(3):31-38. PubMed ID: 28164176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRCA1 deficiency is a recurrent event in early-onset triple-negative breast cancer: a comprehensive analysis of germline mutations and somatic promoter methylation.
    Brianese RC; Nakamura KDM; Almeida FGDSR; Ramalho RF; Barros BDF; Ferreira ENE; Formiga MNDC; de Andrade VP; de Lima VCC; Carraro DM
    Breast Cancer Res Treat; 2018 Feb; 167(3):803-814. PubMed ID: 29116469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.